The Life Sciences Report: Alan, what is your current theme?
Alan Carr: I focus on the broad umbrella of CNS, metabolic and infectious disease, but several specific and timely themes interest me, including rare disease, weight loss, antibiotics and hepatitis C (HCV).
TLSR: Can we talk about the antibiotic theme first?
AC: Yes. I spend a significant amount of time on that space.
TLSR: What would be the sweet spot in terms of growth potential for investors?
AC: Resistance to antibiotics is a continuing problem and represents an unmet need. For a number … [visit site to read more]